Format

Send to

Choose Destination
Oncotarget. 2018 Jul 24;9(57):30946-30961. doi: 10.18632/oncotarget.25697. eCollection 2018 Jul 24.

Patient derived renal cell carcinoma xenografts exhibit distinct sensitivity patterns in response to antiangiogenic therapy and constitute a suitable tool for biomarker development.

Author information

1
Charles River Discovery Research Services Germany GmbH, Freiburg, Germany.
2
LfB - Lehrstuhl für Bildverarbeitung, RWTH Aachen University, Aachen, Germany.
3
Department of Radiation Oncology, University Hospital of Würzburg, Würzburg, Germany.
4
Dr. Margarete Fischer-Bosch - Institut für Klinische Pharmakologie, Stuttgart, Germany.
5
Department of Urology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
6
Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.
7
Department of Experimental Oncology, University of Alberta, 5-142W Katz Group Centre, Edmonton, Canada.
8
Department of Urology, Medical Center Johannes Gutenberg University, Mainz, Germany.

Abstract

Systemic treatment is necessary for one third of patients with renal cell carcinoma. No valid biomarker is currently available to tailor personalized therapy. In this study we established a representative panel of patient derived xenograft (PDX) mouse models from patients with renal cell carcinomas and determined serum levels of high mobility group B1 (HMGB1) protein under treatment with sunitinib, pazopanib, sorafenib, axitinib, temsirolimus and bevacizumab. Serum HMGB1 levels were significantly higher in a subset of the PDX collection, which exhibited slower tumor growth during subsequent passages than tumors with low HMGB1 serum levels. Pre-treatment PDX serum HMGB1 levels also correlated with response to systemic treatment: PDX models with high HMGB1 levels predicted response to bevacizumab. Taken together, we provide for the first time evidence that the damage associated molecular pattern biomarker HMGB1 can predict response to systemic treatment with bevacizumab. Our data support the future evaluation of HMGB1 as a predictive biomarker for bevacizumab sensitivity in patients with renal cell carcinoma.

KEYWORDS:

HMGB1; VEGF; bevacizumab; damage associated molecular pattern; renal cell carcinoma

Conflict of interest statement

CONFLICTS OF INTEREST JS, KK, AM, ML and ALP are salaried employees of Charles River Discovery, Freiburg, Germany. This employment does not alter our adherence to all the journal policies on sharing data and materials. All experiments were approved by the local ethics committee with written informed consent. The authors declare no competing financial interest.

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center